Your Notifications
All done, no notifications

What is a Hormone Receptor-Positive Breast Cancer?

Hormone receptor-positive breast cancer is a type of breast cancer in which cancer cells have receptors for estrogen (ER), progesterone (PR), or both hormones. These hormones can stimulate the growth of hormone receptor-positive cancer cells.

Hormone receptor-positive breast cancer can occur at different stages, and treatment depends on the tumour size, lymph-node involvement, grade, HER2 status, menopausal status, genomic characteristics, and overall health.

What is the Importance of Timely Treatment?

Timely diagnosis and treatment of hormone receptor-positive breast cancer can help control tumour growth and reduce the risk of recurrence or spread to other parts of the body. Depending on the stage and biological features, treatment may also include surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy. Long-term follow-up is important because hormone receptor-positive breast cancer can recur even several years after the initial treatment.

What are the Common Symptoms of Hormone Receptor-Positive Breast Cancer?

  • A new lump or thickening in the breast
  • A change in breast size or shape
  • Changes in the skin of the breast
  • Nipple inversion or other nipple changes
  • Unusual nipple discharge, including bloody discharge
  • Persistent breast or nipple pain
  • Swelling or a lump in the underarm area
  • Changes in the appearance or texture of the breast

Causes and Risk Factors of Hormone Receptor-Positive Breast Cancer

Causes

  • Hormone receptor-positive breast cancer develops when genetic and molecular changes cause breast cells to grow and divide abnormally.
  • The exact cause is usually not identifiable in an individual patient. Hormonal exposure, inherited genetic susceptibility, age-related cellular changes, and other biological factors may contribute to risk.

Risk Factors

  • Increasing age
  • Family history of breast or ovarian cancer
  • Inherited genetic mutations such as BRCA1 or BRCA2
  • Longer lifetime exposure to estrogen
  • Early onset of menstruation or later menopause
  • Having no pregnancies or having a first pregnancy at a later age
  • Use of certain menopausal hormone therapies
  • Alcohol consumption
  • Overweight or obesity after menopause
  • Previous radiation exposure to the chest at a young age
  • Certain breast conditions associated with increased cancer risk

Latest Research and Technologies in the Treatment of Hormone Receptor-Positive Breast Cancer in India

  • Treatment of hormone receptor-positive breast cancer is increasingly guided by tumour biology, genomic characteristics, and molecular biomarkers. Endocrine therapy remains a major treatment approach, while CDK4/6 inhibitors have expanded treatment options for selected patients. In advanced or metastatic disease, molecular testing may identify alterations. Newer endocrine approaches, including oral selective estrogen receptor degraders, are also expanding options for selected patients with endocrine-resistant disease. Genomic assays may help estimate recurrence risk and inform chemotherapy decisions in selected early-stage, hormone receptor-positive and HER2-negative cancers.

Treatment options for Hormone Receptor-Positive Breast Cancer

Mastectomy : A mastectomy is a surgical procedure to remove all or part of a breast, most commonly used to treat or prevent breast cancer.


Cost Start From 4250Explore Options

Radiotherapy: Radiation therapy is commonly used after breast-conserving surgery and may be recommended after mastectomy or lymph-node surgery in selected patients.

Chemotherapy : Chemotherapy may be recommended when the risk of recurrence is sufficiently high or when tumour and genomic characteristics suggest a potential benefit.


Cost Start From 300Explore Options

CDK4/6 inhibitors: Medicines may be used with endocrine therapy in selected early-stage or advanced hormone receptor-positive breast cancers.

Targeted therapy : Targeted medicines may be considered when specific molecular alterations or HER2 expression are identified.


Cost Start From 1000Explore Options

Immunotherapy : Immunotherapy is used in selected breast cancer settings based on tumour subtype and biomarkers; it is not required for all hormone receptor-positive cancers.


Cost Start From 1500Explore Options

Hormone therapy : It is also known as endocrine therapy, is the primary treatment for Hormone Receptor-Positive (HR+) breast cancer. Hormone therapy does not replace standard chemotherapy or surgery; rather, it acts as a full-body (systemic) treatment to stop the body's natural hormones from feeding remaining cancer cells.


Cost Start From 1500Explore Options

  • Clinical assessment:
    • Core needle biopsy: Provides tissue for confirming breast cancer.
    • Histopathology: Determines the cancer type, grade, and other microscopic characteristics.
    • ER and PR testing: Determines whether the tumour is hormone receptor-positive.
    • HER2 testing: Determines whether HER2-targeted treatment may be appropriate.
    • Ki-67: May be assessed in selected settings as a marker of tumour cell proliferation.
    • Genomic assays: Tests such as Oncotype DX or other validated assays may help estimate recurrence risk and potential chemotherapy benefit in selected early-stage HR-positive/HER2-negative cancers.
    • Genetic testing: BRCA1, BRCA2, and other hereditary cancer genes may be evaluated in patients who meet appropriate clinical criteria.
  • Imaging Tests:
    • Mammography: Helps identify suspicious breast changes and is commonly used for diagnosis and screening.
    • Breast ultrasound: Helps evaluate breast lumps and distinguish solid from cystic lesions.
    • Breast MRI: May be recommended for selected patients, particularly when additional assessment is needed.
    • CT or PET/CT: May be used for staging in selected patients with locally advanced or metastatic disease.
    • Bone imaging: Consider a bone scan or other imaging when bone involvement is suspected.
    • Additional imaging: Imaging of specific organs may be performed when symptoms or clinical findings suggest possible metastatic disease.

MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive rehabilitation services designed to support Hormone Receptor-Positive Breast Cancer patients in India. These services include:

  • Post-surgical rehabilitation: Exercises to restore shoulder movement, arm strength, and upper-body function after breast or lymph-node surgery.
  • Lymphedema management: Assessment, exercise, compression strategies, and specialised therapy when swelling develops in the arm or breast.
  • Physical activity: Gradual aerobic and resistance exercise can help improve strength, mobility, cardiovascular health, and fatigue.
  • Bone health support: Patients receiving aromatase inhibitors or other treatments that affect bone health may require exercise, nutritional guidance, and monitoring.
  • Fatigue management: Activity planning, sleep support, nutrition, and energy-conservation strategies can help manage treatment-related fatigue.
  • Psychological support: Counselling and supportive-care services can help patients manage anxiety, emotional stress, body-image concerns, and treatment-related challenges.
  • Medicines for hormone receptor-positive breast cancer are selected according to the stage, menopausal status, HER2 status, molecular profile, previous treatment, and treatment goals. For selected patients with advanced or high-risk disease, endocrine therapy may be combined with CDK4/6 inhibitors. Consider molecularly targeted medicines when specific alterations. Oral estrogen-receptor-directed therapies may also be used in selected patients with endocrine-resistant disease. Supportive medicines may be prescribed to manage treatment-related symptoms, protect bone health, control nausea or pain, and address other side effects.

Instantly Connect with our Specialists

Doctor 1
Doctor 2
Doctor 3
Doctor 4
Doctor 5
Doctor 6
Doctor 7
Doctor 8

Hospitals for Hormone Receptor-Positive Breast Cancer in India

Max Super Specialty Hospital, Vaishali: Top Doctors, and Reviews
Max Super Specialty Hospital, Vaishali

Ghaziabad, India

  • Max Super Speciality Hospital, Vaishali, Ghaziabad, is a leading multi-speciality hospital with 387+ beds and 37+ clinical specialities, offering advanced care in Cardiology, Neuro Sciences, Oncology, Orthopaedics, Transplants, Gastroenterology, and Reconstructive Surgery.
  • Supported by 389+ doctors and 1038+ trained staff, the hospital combines state-of-the-art technology, including robotic surgery and advanced imaging systems, with compassionate, patient-centred care.
  • Accredited by NABH and NABL, Max Vaishali is a trusted destination for both domestic and international patients seeking high-quality, integrated medical services.
Message Us
Max Hospital, Gurgaon: Top Doctors, and Reviews
Max Hospital, Gurgaon

Gurgaon, India

  • Max Hospital Gurugram is a leading multi-speciality healthcare centre in Haryana, renowned for its advanced clinical expertise and patient-focused care.
  • Established in 2007, it is part of the trusted Max Healthcare network and has treated over 500,000 patients across 35+ specialities.
  • The hospital is equipped with modern medical technology, internationally trained doctors, and superior clinical infrastructure.
  • Known for its excellence in Cardiology, Oncology, Neurosciences, Orthopaedics, Gastroenterology, and Women & Child Care, Max Hospital is a preferred choice for both domestic and international patients seeking high-quality treatment with compassionate care.
Message Us
OncoCare Cancer Centre: Top Doctors, and Reviews
OncoCare Cancer Centre

Amroha, India

Onco Care Cancer Hospital is one of the Top Cancer Treatment Centres in India focused on delivering the best and most affordable treatment for cancer patients with superior quality of care, and the latest treatment options. Chemotherapy, radiation, immunotherapy, and targeted treatment are among the available therapies in the hospital complemented by modern technological and equipment systems.

Both oncologists, surgeons, nursing personnel as well as other staff members, all contribute to discussions and come up with individualized treatment plans for patients. Realizing that traveling abroad for treatment is a tough decision for a family, Onco Care is dedicated to research and innovation as well as trying to deliver the best care now and in the future. Their interventions are to deliver medical and emotional needs and to give ‘a home of hope’ for every individual patient.

Message Us

Our Services to better your experience

Opinion & Option

We submit the most accurate opinion and options from one or more countries for your review

Consult Privately

Consult with a certified specialist privately on our telemedicine platform even before you decide to travel

Logistics

We handle flights, visas, transfers, and accommodation—so you can focus on your health.

Recovery

Our In-house rehabilitation service packages to better your recovery and treatment outcome

Why Choose India for Hormone Receptor-Positive Breast Cancer Treatment?

  • Experienced breast cancer specialists: Breast surgeons, medical oncologists, radiation oncologists, pathologists, radiologists, and other specialists can contribute to treatment planning.
  • Advanced diagnostic facilities: Mammography, ultrasound, breast MRI, biopsy, pathology, hormone receptor testing, HER2 testing, genetic testing, and selected genomic assays can support personalised treatment planning.
  • Modern treatment options: Eligible patients may have access to breast-conserving surgery, mastectomy, advanced radiotherapy, endocrine therapy, chemotherapy, CDK4/6 inhibitors, targeted therapies, and other systemic treatments.
  • Multidisciplinary cancer care: Treatment planning may involve breast specialists, oncologists, pathologists, radiologists, genetic counsellors, nutritionists, physiotherapists, and rehabilitation professionals.
  • International patient support: Many major hospitals provide dedicated international patient services, including medical coordination, documentation, accommodation, travel assistance, and follow-up planning.

Frequently Asked Questions

Recovery varies according to the cancer stage and treatment plan. Recovery from breast surgery may take several weeks, while chemotherapy and radiotherapy can require additional recovery time. Endocrine therapy is often prescribed for several years, so care may include long-term follow-up and management of treatment-related effects.

Yes. Most patients can walk and remain physically active when their health permits. Regular movement is generally encouraged during and after treatment, although activity levels may need to be adjusted based on surgery, fatigue, treatment side effects, and medical advice.

Many specialised Indian cancer centres provide modern diagnostic and treatment facilities, including digital mammography, breast MRI, advanced pathology, hormone receptor and HER2 testing, genomic testing in selected cases, breast-conserving surgery, advanced radiotherapy, endocrine therapy, targeted therapy, and chemotherapy.

Many major Indian hospitals have dedicated international patient departments that assist with medical appointments, treatment coordination, travel documentation, accommodation, interpretation, and follow-up arrangements.

Consider a breast cancer centre with experienced breast surgeons and oncologists, comprehensive pathology and biomarker testing, multidisciplinary tumour-board care, access to modern systemic therapies, radiation oncology, rehabilitation, and supportive-care services. Patients may also consider the hospital's experience with their specific stage and subtype of breast cancer.

There is no single success rate for hormone receptor-positive breast cancer. Outcomes depend on the stage at diagnosis, tumour size, lymph-node involvement, grade, ER and PR status, HER2 status, genomic characteristics, response to treatment, and overall health. Early-stage disease generally has different outcomes from locally advanced or metastatic disease.

India has specialised cancer centres with breast surgeons, medical oncologists, radiation oncologists, and other specialists experienced in treating hormone receptor-positive breast cancer. Patients should review the specialist's experience, the hospital's breast cancer services, diagnostic capabilities, and multidisciplinary treatment approach.

Risks depend on the treatment used. Surgery may cause pain, infection, bleeding, changes in breast sensation, or shoulder-movement problems. Radiotherapy can cause skin changes, fatigue, and other site-specific effects. Chemotherapy may cause nausea, fatigue, hair loss, low blood counts, and increased infection risk. Endocrine therapy may cause hot flashes, joint symptoms, sexual or reproductive effects, and changes in bone health.

After diagnosis, consult a multidisciplinary breast cancer team to confirm the tumour type, stage, hormone receptor status, and HER2 status. Discuss the pathology report, imaging results, genetic or genomic testing when appropriate, available treatment options, expected benefits and risks, and whether a second pathology or specialist opinion would be useful.

Hormone receptor-positive breast cancer does not typically cause physical deformities. However, breast surgery may change breast shape, size, or appearance, and lymph-node treatment can sometimes contribute to arm or breast swelling. Breast reconstruction and rehabilitation may be options for selected patients.

Yes. Breast cancer and its treatment can affect physical health, energy levels, body image, emotional well-being, sexual health, work, and daily activities. Endocrine therapy may also cause menopausal or musculoskeletal symptoms in some patients. Rehabilitation, symptom management, psychological support, and appropriate exercise can help address these effects.

Yes. Without appropriate treatment, hormone receptor-positive breast cancer can continue to grow and may spread to lymph nodes or distant organs. Even after successful initial treatment, hormone receptor-positive breast cancer can have a risk of recurrence, including recurrence many years later, which is why long-term follow-up is important.

There is no ensured way to prevent hormone receptor-positive breast cancer. Risk may be reduced by maintaining a healthy weight, staying physically active, limiting alcohol, avoiding tobacco, and following recommended breast cancer screening. People with a strong family history or inherited cancer-risk mutations may benefit from genetic counselling and personalised risk-reduction strategies.

Yes. Hormone receptor-positive breast cancer is a common biological subtype of breast cancer and becomes more frequent with increasing age. Risk is also influenced by family history, inherited genetic susceptibility, reproductive and hormonal factors, previous chest radiation, alcohol use, and other established breast cancer risk factors. Although breast cancer is much more common in women, it can also occur in men.